



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Chris DOTT et al

Serial No.: 10/581671

Filed: June 5, 2006

For: BOTULINUM TOXIN TREATMENT
OF SPASTIC BLADDER

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR §1.56, and in accordance with 37 CFR §§1.97 and 1.98, Applicant(s), through the undersigned attorney, submits this Information Disclosure Statement. The patents, publications or other information submitted herewith are listed on the attached Form PTO-1449 and copies are attached excluding U.S. patents and publications.


The documents listed on the attached Form PTO-1449 were cited in the International Search Report. A copy of the ISR is attached.

Documents AD and AG listed on Form PTO-1449 were also cited in a Great Britain Search Report in a counterpart Great Britain patent application. A copy of the British Search Report is enclosed.

In accordance with 37 CFR §1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits of the above-identified application.


Respectfully submitted,

JACOBSON HOLMAN PLLC

By: 

John C. Holman
Registration No. 22,769
400 Seventh Street, N.W.
Washington, DC 20004-2218
(202) 638-6666

Atty. Dkt. No.: P71305US0
Date: October 13, 2006



JACOBSON HOLMAN PLLC
400 SEVENTH STREET, N.W.
WASHINGTON, D.C. 20004-2201

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.: P71305US0
SERIAL NO.: 10/581671
APPLICANT(S): DOTT et al

GROUP ART UNIT: _____
FILING DATE: June 5, 2006
TODAY'S DATE: October 13, 2006

U. S. PATENT DOCUMENTS

*EXAMINER <u>INITIAL</u>	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE <u>If Appropriate</u>
AA	<u>5437291</u>	<u>08/01/95</u>	<u>Pasricha et al</u>	<u>128</u>	<u>898</u>	_____
AB	<u>6638246</u>	<u>10/28/03</u>	<u>Naimark et al</u>	<u>604</u>	<u>103</u>	_____
AC	<u>2002/0099356</u>	<u>07/25/02</u>	<u>Unger et al</u>	<u>604</u>	<u>501</u>	_____
AD	<u>2003/0108597</u>	<u>06/12/03</u>	<u>Chancellor et al</u>	<u>424</u>	<u>450</u>	_____
AE	<u>2003/0211975</u>	<u>11/13/03</u>	<u>Unger</u>	<u>514</u>	<u>2</u>	_____

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION <u>YES</u> <u>NO</u>
AF	<u>WO99/03483</u>	<u>01/28/99</u>	<u>WIPO</u>	_____	_____	_____
AG	<u>WO04/010934</u>	<u>02/05/04</u>	<u>WIPO</u>	_____	_____	_____
AH	_____	_____	_____	_____	_____	_____

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	<u>Dykstra et al, ARCH PHYS MED REHABIL Vol 71, Jan. 1990, pgs. 24-26, Treatment of Detrusor-Sphincter Dyssynergia with Botulinum..</u>
AJ	<u>Yokoyama et al, ACTA MED Vol 56, No 6, 2002, pgs. 271-277, Botulinum Toxin Treatment of Urethral and Bladder Dysfunction</u>
AK	_____

EXAMINER _____ DATE CONSIDERED _____

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)